Industry Bulletins | July 30, 2020
Tris Pharma & KYE Pharmaceuticals Announce Exclusive License Agreement To Commercialize Tris ADHD Products In Canada
Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with products approved by the U.S. Food and Drug Administration for the treatment of attention deficit hyperactivity disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (KYE), a private company headquartered in Mississauga, Ontario and focused on the Canadian market, announced that they have entered into an agreement whereby KYE received exclusive rights to commercialize Tris’ FDA-approved ADHD product portfolio in Canada. Under the terms of this agreement, KYE will also handle all ongoing Canadian regulatory activities for the products. Financial terms of the agreement were not disclosed.
Doug Reynolds . . .